Al-Madina Pharmaceuticals Limited announcements
60 Dhaka Stock Exchange announcements for Al-Madina Pharmaceuticals Limited (AMPL) since 2023: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (29).
- The company has informed that they are trying to develop the Export of Pharma products. At this moment, they have comple
The company has informed that they are trying to develop the Export of Pharma products. At this moment, they have completed agreement with Moringa Pharmaceutical, Ethiopia.
- The company has informed that it has completed the export of the Pharma products amounting to USD70,960.56 through Bill
The company has informed that it has completed the export of the Pharma products amounting to USD70,960.56 through Bill of Lading No ALMDBNF25966 to Hezaj Ltd, Afghanistan.
- The company has informed that Al-Madina Pharmaceuticals Ltd. has delivered the Pharma products to the Chittagong Port am
The company has informed that Al-Madina Pharmaceuticals Ltd. has delivered the Pharma products to the Chittagong Port amounting to USD 70,960.56 for shipping to Hezaj Ltd, Afghanistan. The company has already received the Expo Form and realized the export proceeds of USD 70,960.56 in advance through Al-Arafah Islami Bank Ltd. The company is now waiting to ship the pharma products to Hezaj Ltd as per the sales contract.
- Mr. Md. Kamrul Alam, a Director of the company, has further informed that he has completed his transfer of 757,500 share
Mr. Md. Kamrul Alam, a Director of the company, has further informed that he has completed his transfer of 757,500 shares of the company to his spouse Ms. Sahela Nahid by way of gift outside the trading system of the Exchange as per declaration disseminated by DSE on 03.12.2025.
- Mr. Md. Billal Hossain, a Director of the company, has further informed that he has completed his transfer of 909,000 sh
Mr. Md. Billal Hossain, a Director of the company, has further informed that he has completed his transfer of 909,000 shares of the company to his spouse Ms. Hosne Ara by way of gift outside the trading system of the Exchange as per declaration disseminated by DSE on 03.12.2025.
- Mr. Md. Zakir Hossain Patwary, a Director of the company, has further informed that he has completed his transfer of 902
Mr. Md. Zakir Hossain Patwary, a Director of the company, has further informed that he has completed his transfer of 902,200 shares of the company to his spouse Ms. Rowshan Ara Mukta by way of gift outside the trading system of the Exchange as per declaration disseminated by DSE on 03.12.2025.
- Mr. Md. Kamrul Alam, a Director of the company, has expressed his intention to transfer 757,500 shares of the company to
Mr. Md. Kamrul Alam, a Director of the company, has expressed his intention to transfer 757,500 shares of the company to his spouse Ms. Sahela Nahid (General Shareholder of the company), by way of gift outside the trading system of the Exchange within next thirty working days with effect from December 01, 2025.
- Mr. Md. Billal Hossain, a Director of the company, has expressed his intention to transfer 909,000 shares of the company
Mr. Md. Billal Hossain, a Director of the company, has expressed his intention to transfer 909,000 shares of the company to his spouse Ms. Hosne Ara (General Shareholder of the company), by way of gift outside the trading system of the Exchange within next thirty working days with effect from December 01, 2025.
- Mr. Md. Zakir Hossain Patwary, a Director of the company, has expressed his intention to transfer 902,200 shares of the
Mr. Md. Zakir Hossain Patwary, a Director of the company, has expressed his intention to transfer 902,200 shares of the company to his spouse Ms. Rowshan Ara Mukta (General Shareholder of the company), by way of gift outside the trading system of the Exchange within next thirty working days with effect from December 01, 2025.
- The company has informed that they entered into an agreement on 15 June 2025 for the sale of selected products to Vista
The company has informed that they entered into an agreement on 15 June 2025 for the sale of selected products to Vista Pharma. To execute this agreement, the Company received a production order for one batch of 5,000 Box of cap. Algaba 50 mg as per the agreed terms and conditions. The Company commenced production on 15.11.2025 in accordance with the production order from Vista Pharma. (cont.)
- (Cont. news of AMPL): The company hopes to deliver the product as soon as possible, and they also expect to receive addi
(Cont. news of AMPL): The company hopes to deliver the product as soon as possible, and they also expect to receive additional production orders in the coming days continuously. (end)
The first part of this announcement is missing from the archive. - Trading of the shares of the company will resume on 05.11.2025.
Trading of the shares of the company will resume on 05.11.2025.
- The company has informed that the Board has confirmed to increase the authorised capital of the company from Tk. 30,00,0
The company has informed that the Board has confirmed to increase the authorised capital of the company from Tk. 30,00,00,000.00 (Taka Thirty Crore) divided into 3,00,00,000 (Three Crore) number of ordinary share @ Tk. 10 (ten) each to Tk. 60,00,00,000.00 (Sixty Crore) divided into 6,00,00,000 (Six Crore) number of ordinary share @ Tk. 10 (ten) each and accordingly the amendments in the Memorandum and Articles of Association of the Company. (cont.)
- (Cont. news of AMPL): Date of EGM: 30.12.2025, Time: 11:10 AM, Venue: Digital Platform through the link: https://almadin
(Cont. news of AMPL): Date of EGM: 30.12.2025, Time: 11:10 AM, Venue: Digital Platform through the link: https://almadinapharma.bdvirtualagm.com. Record Date for EGM: 04.11.2025. (end)
The first part of this announcement is missing from the archive. - Trading of the shares of the company will remain suspended on record date i.e., 04.11.2025 for AGM & EGM.
Trading of the shares of the company will remain suspended on record date i.e., 04.11.2025 for AGM & EGM.
- Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 02.11.2025 to 03.11.2025 and trading of the shares will remain suspended on record date i.e., 04.11.2025.
- Mr. Md. Zakir Hossain Patwary, Managing Director of the Company, has completed his sale of 4,61,300 shares of the Compan
Mr. Md. Zakir Hossain Patwary, Managing Director of the Company, has completed his sale of 4,61,300 shares of the Company at prevailing market price through Dhaka Stock Exchange PLC. (DSE) as per declaration disseminated by DSE on 13.10.2025.
- The company has made an agreement dated on 15.06.2025 for sale of selected products to the Vista Pharma. For executing t
The company has made an agreement dated on 15.06.2025 for sale of selected products to the Vista Pharma. For executing this agreement, the company has got the production order 1 Batch Qty 5,000 PC of tab. Gastrazole 20 mg as per agreement terms and conditions. The Company has started production on 16.10.2025 as per production order of the Vista Pharma.
- The company has informed that they started export from 2024. On 13.10.2025 the Company has started the production for th
The company has informed that they started export from 2024. On 13.10.2025 the Company has started the production for the export of Pharma products to Hejaz Ltd for another upcoming partial shipment as per sales contract no AMPL/SC/IMD03/0925/002 USD 1,23,217.998. The company hopes that they will be able to make shipment of the export of Pharma products to Hejaz Ltd as per terms and conditions of sales contract accordingly along with they are expecting to get more export order in upcoming days.
- Mr. Md. Zakir Hossain Patwary, Managing Director of the Company, has expressed his intention to sell 4,61,300 shares out
Mr. Md. Zakir Hossain Patwary, Managing Director of the Company, has expressed his intention to sell 4,61,300 shares out of his holding of 6,412,500 shares of the Company at prevailing market price (In the Public Market and/or Block) through Dhaka Stock Exchange PLC. (DSE) within next 45 working days.
- The Board of Directors has recommended 12\% Cash Dividend for General Shareholders and 1\% Cash Dividend for Sponsors an
The Board of Directors has recommended 12\% Cash Dividend for General Shareholders and 1\% Cash Dividend for Sponsors and or Directors for the year ended June 30, 2025. The Quantity of Securities of Directors (number of shares): 1,42,50,000 shares and proposed dividend amount is Tk. 14,25,000.00. General Shareholders (Number of Shares) 61,50,000 shares and proposed dividend amount is Tk. 73,80,000.00. (cont.)
- (Cont. News of AMPL): Date of AGM: 30.12.2025, Time: 11:30 AM, Venue: Digital Platform through the link: https://almadin
(Cont. News of AMPL): Date of AGM: 30.12.2025, Time: 11:30 AM, Venue: Digital Platform through the link: https://almadinapharma.bdvirtualagm.com. Record Date: 04.11.2025. The Company has also reported EPS of Tk. 0.58, NAV per share of Tk. 20.61 (with revaluation), NAV per share of Tk. 13.80 (without revaluation) and NOCFPS of Tk. 0.94 for the year ended June 30, 2025 as against Tk. 0.87, Tk. 20.39, Tk. 13.58 and Tk. 2.50 respectively for the year ended June 30, 2024. (end)
The first part of this announcement is missing from the archive. - There will be no price limit on the trading of the shares of the Company today (07.10.2025) following its corporate decl
There will be no price limit on the trading of the shares of the Company today (07.10.2025) following its corporate declaration.
- As per Regulation 17(1) of the Dhaka Stock Exchange (Listing of Small Capital Companies) Regulations, 2019, the Company
As per Regulation 17(1) of the Dhaka Stock Exchange (Listing of Small Capital Companies) Regulations, 2019, the Company has informed that a meeting of the Board of Directors will be held on October 06, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- In response to the DSE query dated August 04, 2025, the company has informed that there is no undisclosed price sensitiv
In response to the DSE query dated August 04, 2025, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Al-Madina Pharmaceuticals Ltd. submitted auditor\'s report regarding status of IPO (Initial Public Offering) Proceeds ut
Al-Madina Pharmaceuticals Ltd. submitted auditor\'s report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the period/quarter ended on June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Al-madina\%20Pharmaceuticals_2025.pdf
- Al-Madina Pharmaceuticals Ltd. submitted auditor\'s report regarding status of IPO (Initial Public Offering) Proceeds ut
Al-Madina Pharmaceuticals Ltd. submitted auditor\'s report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for period ended 31 March, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Al-Madina\%20Pharmaceuticals\%20Ltd_25.pdf
- The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shar
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Alpha Credit Rating PLC (Alpha Rating) has assigned the Surveillance rating of the Company as \"A-\" in the long term an
Alpha Credit Rating PLC (Alpha Rating) has assigned the Surveillance rating of the Company as \"A-\" in the long term and \"ST-2\" in the short term along with Stable outlook based on the audited financial statements as on June 30, 2024 and relevant qualitative information till January 01, 2025.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.